MarketAnalysisMarketAnalysis
NASDAQ:ALNY

Alnylam Pharmaceuticals, Inc. - NASDAQ:ALNY - Comprehensive analysis

Free evaluation through quantitative algorithms Alnylam Pharmaceuticals, Inc. - NASDAQ:ALNY

Quant Rating

1

Strong Sell

2

Sell

3

Hold

4

Buy

5

Strong Buy


The overall quant rating is not an average of the factor grades listed.Instead, it gives greater weight to the metrics with the strongest predictive value.

Growth-Scoring Model Detail

Name

Fatcor
Percentage

Total Revenue Growth Over Prior Year

23

Market

96

Sector

77

Gross Profit Growth Over Prior Year

26.8

Market

93

Sector

81

EBITDA Growth Over Prior Year

0

Market

0

Sector

0

EBITA Growth Over Prior Year

0

Market

0

Sector

0

EBIT Growth Over Prior Year

0

Market

0

Sector

0

Earnings from Cont. Ops. Growth Over Prior Year

0

Market

0

Sector

0

Net Income Growth Over Prior Year

0

Market

0

Sector

0

Normalized Net Income Growth Over Prior Year

0

Market

0

Sector

0

Diluted EPS before Extra Growth Over Prior Year

0

Market

0

Sector

0

A/R Growth Over Prior Year

23.6

Market

90

Sector

82

Inventory Growth Over Prior Year

-11.93

Market

9

Sector

13

PPE Net Growth Over Prior Year

-4.39

Market

17

Sector

48

Total Assets Growth Over Prior Year

10.71

Market

83

Sector

68

Tangible Book Value Growth Over Prior Year

0

Market

0

Sector

0

Common Equity Growth Over Prior Year

0

Market

0

Sector

0

Cash from Ops. Growth Over Prior Year

0

Market

0

Sector

0

CAPEX Growth Over Prior Year

-44.9

Market

3

Sector

26

Dividend per Share Growth Over Prior Year

0

Market

36

Sector

48

Levered Free Cash Flow Growth Over Prior Year

92

Market

91

Sector

81

Unlevered Free Cash Flow Growth Over Prior Year

60

Market

87

Sector

76

Profitability-Scoring Model Detail

Name

Fatcor
Percentage

Gross Margin %

86

Market

96

Sector

86

SG&A Margin %

43.4

Market

93

Sector

53

EBITDA Margin %

-5.35

Market

1

Sector

28

EBITA Margin %

-7.87

Market

1

Sector

29

EBIT Margin %

-7.87

Market

1

Sector

31

Earnings from Cont. Ops Margin %

-12.37

Market

3

Sector

32

Net Income Margin %

-12.37

Market

3

Sector

32

Net Income Avail. for Common Margin %

-12.37

Market

3

Sector

32

Normalized Net Income Margin %

-10.41

Market

1

Sector

28

Levered Free Cash Flow Margin %

8.8

Market

47

Sector

76

Unlevered Free Cash Flow Margin %

12.75

Market

55

Sector

80

Return on Assets %

-2.74

Market

1

Sector

63

Return on Capital %

-4.19

Market

1

Sector

62

Return on Equity %

0

Market

0

Sector

0

Return on Common Equity %

0

Market

0

Sector

0

Total Asset Turnover

0.56

Market

57

Sector

68

Sub-Scoring Model

Valuation
Momentum
Growth
Profitability
80
60
40
20
Valuation: 30
Momentum: 57
Growth: 60
Profitability: 26

Valuation-Scoring Model Detail

Name

Fatcor
Percentage

TEV/LTM Total Revenue

13.84

Market

96

Sector

83

TEV/LTM EBITDA

0

Market

0

Sector

0

P/LTM Normalized EPS

0

Market

0

Sector

0

P/BV

0

Market

0

Sector

0

TEV/LTM Unlevered FCF

109

Market

99

Sector

97

Momentum-Scoring Model Detail

Name

Fatcor
Percentage

1M Price Performance

-0.72

Market

67

Sector

79

3M Price Performance

-7.07

Market

49

Sector

74

6M Price Performance

-13.86

Market

35

Sector

64

9M Price Performance

-7.87

Market

38

Sector

73

1Y Price Performance

58

Market

97

Sector

93

Start analyzing Alnylam Pharmaceuticals, Inc. - NASDAQ:ALNY with easy-to-understand research reports

Start analyzing Recent popular companies with easy-to-understand research reports